Sugi Predict

Sugi Predict / Targets / CDC7

CDC7

Cell division cycle 7-related protein kinase · O00311 · CDC7 on Sugi Atlas →

84,364 patent compounds predicted against CDC7, 48,014 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL289730 SCHEMBL289730 0.79 16/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL289729) 0.77 16/20
SCHEMBL38093 SCHEMBL38093 0.35 12/20
SCHEMBL290243 SCHEMBL290243 0.79 11/20
SCHEMBL289784 SCHEMBL289784 0.62 11/20
SCHEMBL289506 SCHEMBL289506 0.62 11/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL289783) 0.61 11/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL383449) 0.61 11/20
SCHEMBL383305 SCHEMBL383305 0.60 11/20
SCHEMBL290427 SCHEMBL290427 0.57 11/20
SCHEMBL290168 SCHEMBL290168 0.54 11/20
SCHEMBL383388 SCHEMBL383388 0.73 10/20
SCHEMBL259291 SCHEMBL259291 0.66 10/20
SCHEMBL289647 SCHEMBL289647 0.64 10/20
SCHEMBL298114 SCHEMBL298114 0.64 10/20
SCHEMBL289549 SCHEMBL289549 0.63 10/20
SCHEMBL383302 SCHEMBL383302 0.62 10/20
SCHEMBL289147 SCHEMBL289147 0.60 10/20
SCHEMBL383356 SCHEMBL383356 0.79 9/20
SCHEMBL290384 SCHEMBL290384 0.75 9/20

Clinical trials — most relevant to CDC7 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) PHASE3COMPLETED
Effect of Silymarin in Metastatic Colorectal Cancer Patients PHASE3UNKNOWN
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer PHASE3RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) PHASE1/PHASE2NOT_YET_RECRUITING
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer PHASE1/PHASE2COMPLETED
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer PHASE2COMPLETED
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
A Clinical Study of TQB3824 in Subjects With Advanced Cancer PHASE1UNKNOWN
A CR-UK Phase I Trial of LY3143921 PHASE1ACTIVE_NOT_RECRUITING
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer PHASE1COMPLETED
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas PHASE1COMPLETED
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer PHASE1NOT_YET_RECRUITING
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas PHASE1COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies nanENROLLING_BY_INVITATION
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Genetic Analysis of Familial Melanoma nanCOMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Molecular Analysis of Thoracic Malignancies nanENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a CDC7 binder may also engage these)

ProteinNameSimilarity
Q9Z0H0 — 1.000 Q9Z0H0 →
Q9STM3 — 0.992 Q9STM3 →
B2GUY1 — 0.991 B2GUY1 →
Q6YY75 — 0.991 Q6YY75 →
Q9FT70 — 0.991 Q9FT70 →
Q9FY74 — 0.991 Q9FY74 →
Q9BXU1 — 0.991 Q9BXU1 →
Q9Z2R9 — 0.990 Q9Z2R9 →
A2A3K4 — 0.989 A2A3K4 →
Q6DFV7 — 0.989 Q6DFV7 →
Q9LJD8 — 0.989 Q9LJD8 →
Q6NPP4 — 0.989 Q6NPP4 →
Q9M1I1 — 0.989 Q9M1I1 →
Q923W1 — 0.989 Q923W1 →
Q94CU5 — 0.988 Q94CU5 →
Q94C95 — 0.988 Q94C95 →
Q9LFA2 — 0.988 Q9LFA2 →
Q9SFB6 — 0.988 Q9SFB6 →
Q6NTJ3 — 0.988 Q6NTJ3 →
Q9Z1J2 — 0.988 Q9Z1J2 →
Q5R667 — 0.988 Q5R667 →
F4JXF1 — 0.988 F4JXF1 →
Q8RX66 — 0.988 Q8RX66 →
Q7TNL3 — 0.988 Q7TNL3 →
Q4R8E0 — 0.988 Q4R8E0 →
Q8L7T6 — 0.988 Q8L7T6 →
Q8WZ64 — 0.988 Q8WZ64 →
A2VDZ4 — 0.988 A2VDZ4 →
Q92613 — 0.988 Q92613 →
O22042 — 0.988 O22042 →